Overview

A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

Status:
Active, not recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

This is a Phase III, multicenter, open-label, randomized and controlled study to compare the efficacy of a consolidation therapy with RIT versus ASCT in patients with FL in CR or PR after second or third line chemotherapy supplemented with rituximab.

Phase:

Phase 3

Details

Lead Sponsor:

Fondazione Italiana Linfomi ONLUS

Treatments:

Antibodies, Monoclonal